Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -38.2% | 57.3% | -35.6% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 20.3% | 61.3% | 42.6% | 61.1% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£0 | £0 | £0 | -£0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -107.5% | -20% | -107.8% | -35.4% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | -£0 | £0 | £0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -138.2% | -32.6% | -113.6% | -46.6% |
| EPS | -0.006 | -0.002 | -0.007 | -0.006 |
| % Growth | -165.2% | 64.6% | -12.1% | – |
| EPS Diluted | -0.006 | -0.002 | -0.007 | -0.006 |
| Weighted Avg Shares Out | 5 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 5 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -109.3% | -19% | -97.3% | -28.9% |